In recent times, laser treatment combined with intravitreal bevacizumab (Avastin) has been used rarely as early investigations to treat patients with aggressive posterior retinopathy of prematurity (ROP). We describe choroidal ruptures that were documented at 10 weeks after this combined treatment in a preterm infant born at 28 weeks gestation with a birth weight of 1190 g. Aggressive posterior ROP was diagnosed at the age of 6 weeks. Initial treatment included bilateral laser ablation, followed immediately by intravitreal bevacizumab (IVB, 0.75 mg) in the right eye. On day 5, a remarkable regression of plus sign and fibrovascular proliferation was noted only in the right eye. At this point, additional laser treatment combined with IVB was given in the left eye, which dramatically resolved plus disease and neovascularization. At 10 weeks after IVB in the left eye, two sites of choroidal ruptures were revealed along the posterior edges of laser scars. There was no evidence of choroidal neovascularization associated with the choroidal ruptures. Choroidal rupture may occur shortly after laser ablation plus IVB treatment for aggressive posterior ROP. This occurrence requires recognition to determine whether it is actually related to the treatment. Long-term follow-up is important for understanding the nature and progression of this potentially serious complication.
Introduction
During the past 3 years, there have been increasing trends of injecting an antiangiogenic agent intravitreally to treat severe retinopathy of prematurity (ROP). This technique has been performed either alone or in combination with laser photocoagulation of the peripheral avascular retina. [1] [2] [3] All the case reports used intravitreal bevacizumab (Avastin, Genentech, South San Francisco, CA, USA), with the dosage varying from 0.4 to 1.25 mg per injection, and the results have been remarkable. Regression of plus disease and neovascularization is usually observed within 1 week after treatment. The only reported possible adverse effect of intravitreal bevacizumab (IVB) in advanced ROP was an acute contraction of the fibrovascular proliferative membrane, which led to progressive tractional retinal detachment. 4 The data from several studies have shown promising results of IVB for severe ROP. However, there is no consensus regarding the benefit of this treatment over conventional laser treatment, as well as the appropriate timing and dosage of this modality. A prospective, randomized, controlled, multicenter clinical trial such as 'Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP)' is currently being conducted to answer these questions before IVB could be established as a standard treatment for ROP. In the mean time, reports of ocular or systemic adverse effects related to IVB would help to refine the treatment guidelines for severe ROP. In this study, we report a case of choroidal ruptures observed shortly after treatment with laser ablation combined with IVB for aggressive posterior ROP and discuss the potential risk factors for this condition.
Case A retrospective chart review was conducted on a preterm male infant being referred to our institute at the age of 6 weeks for further treatment of severe ROP in both eyes. The patient was born at 28 weeks gestation with a birth weight of 1190 g to a 17-year-old mother and a 19-year-old father. The APGAR scores at 1 and 5 min were 9 and 9, respectively. At the age of 2 weeks (postmenstrual age, of 30 weeks), the patient developed respiratory distress syndrome and was treated successfully with mechanical ventilation and surfactant. The initial fundus examination was carried out at the age of 6 weeks when the diagnosis of severe ROP was made, and the patient was immediately referred to our attention.
Fundus examination showed distinctive plus disease with stage 3 ROP in zone I of both eyes. Anterior segment examination showed dilation of the existing tunica vasculosa lentis in both eyes. The pupils were semidilated with a diameter of 7 mm. The diagnosis of aggressive posterior ROP was made and informed consent was obtained after discussion with the parents regarding the risks and benefits of laser treatment and IVB. Both eyes were treated with laser photocoagulation to the avascular retina. An indirect diode laser system was used with power ranging from 270 to 300 mW and a pulse duration of 200 msec. The number of laser burns applied to the right and left eye was 1871 and 1305 spots, respectively. Although disease severity was similar in both eyes, IVB (0.75 mg) was injected only into the right eye because of insufficient data on short-and long-term adverse effects of this modality.
Follow-up examination on day 5 after treatment showed a remarkable regression of tunica vasculosa lentis, plus disease and neovascularization in the right eye. For the left eye, although the plus sign was regressed, we still observed the remaining of tunica vasculosa lentis and active fibrovascular proliferation (Figure 1) . At this point, additional diode laser photocoagulation was carried out (laser power 200 mW, duration 200 msec, number of laser application 1129 spots), together with 0.75 mg of IVB in the left eye. Serial follow-up examination every 3-4 weeks showed continuing regression of plus disease and neovascularization in both eyes. At 10 weeks after IVB in the left eye, we observed two white, curvilinear, crescent-shaped streaks along the posterior edge of the laser scars in the left eye (Figure 2 ). These lesions were located at the inferonasal and superotemporal quadrants and were concentric to the optic disc. The overlying retina and all other retinal areas appeared intact. There was no evidence of choroidal neovascularization arising from the lesions.
Discussion
The pathophysiology of ROP involves hypoxic retina-induced vascular endothelial growth factor production, followed by retinal neovascularization. At present, intravitreal anti-vascular endothelial growth factor drug injection has been used as compassionate care for severe ROP patients with good response.
Our patient received laser treatment combined with IVB and developed a characteristic feature of choroidal rupture, the condition that generally results from blunt ocular injury. 5 For infants, there was only one report of choroidal rupture associated with forceps delivery, 6 which was not the case in our patient. The pathology of traumatic choroidal rupture involves breaks in the choroid, the Bruch's membrane and the retinal pigment epithelium (RPE). Two types of choroidal rupture are described, direct and indirect. For direct choroidal rupture, the lesion is located at the site of injury. For indirect type, which is more common, the lesion occurs posteriorly and may involve the macula and the optic disc. The pathophysiology of traumatic choroidal rupture involves the damage of choriocapillaris and less resistance to mechanical injury of the Bruch's membrane compared with the retina and the sclera, which results in breaks in the Bruch's membrane after compressive ocular injury. Choroidal neovascularization may penetrate through these breaks into the retina and may cause visual impairment if it occurs in the macular area.
As there has been no report on laser photocoagulation as a cause of choroidal rupture, we speculated that our patient developed this condition because of the dual effects of laser ablation and IVB. Previous study on the histopathological findings in an eye with threshold ROP treated with diode laser ablation showed chorioretinal scarring with retinal atrophy and gliosis, loss of RPE, and extensive atrophy of the choriocapillaris and larger vessels. 7 Although a recent study in embryonic/fetal human eyes showed that maturation of the choriocapillaris with fenestrations occurred by 22 weeks gestation, 8 previous studies indicated that the RPE-derived vascular endothelial growth factor was essential for the development and maintenance of the choriocapillaris from the embryonic stage to adulthood. 9, 10 Therefore, an inactivation of vascular endothelial growth factor expression in the RPE may result in the absence or abnormal structure of the choriocapillaris. A combination of these two effects, laser and IVB, could result in a significant destruction of the choroid and RPE leading to choroidal rupture. As we performed laser ablation in the left eye more heavily than in the right eye, this could be a potential risk factor for developing choroidal rupture. Regarding the amount of IVB, we used a dosage of 0.75 mg, which is not the minimal dose reported for ROP treatment. This could also be another risk factor. Reducing the number and power setting of laser burns, as well as refining the dosage of an antiangiogenic agent, may help prevent this potentially serious complication.
In conclusion, there was an association between choroidal ruptures and laser ablation combined with IVB treatment. Although not necessarily cause and effect based on the single case report, this finding requires careful attention of all medical practitioners taking care of ROP patients. Long-term follow-up is important to understand the nature and progression of this condition.
